Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Alnylam Pharmaceuticals Inc.
Headquarters: Cambridge, MA, United States of America
Website: http://www.alnylam.com
Year Founded: 2002
Status: Public
Industry Sector: HealthTechnology
CEO: Yvonne L. Greenstreet, MD, MBA
Number Of Employees: 2,230
Enterprise Value: $30,086,471,810
PE Ratio: -103.26
Exchange/Ticker 1: NASDAQ:ALNY
Exchange/Ticker 2: N/A
Latest Market Cap: $29,178,200,064
BioCentury | Apr 4, 2025
Data Byte
FDA’s six new product approvals in March
First drug for Prader-Willi hyperphagia, first Xolair biosimilar
BioCentury | Apr 1, 2025
Product Development
Oral PCSK9 inhibition: Will co-formulation drive success?
AZ’s latest data position AZD0780 as slightly less effective but more convenient than PCSK9 competition
BioCentury | Mar 20, 2025
Regulation
Amvuttra’s label expansion lifts Alnylam toward five-year goals
Non-GAAP profitability in sight as RNAi therapeutic adds cardiomyopathy indication alongside previous amyloidosis approval
BioCentury | Mar 14, 2025
Data Byte
Ten PDUFA dates on FDA’s March agenda
Upcoming decisions include a label expansion for Alnylam’s Amvuttra, a new siRNA therapy for hemophilia, and more
BioCentury | Feb 28, 2025
Product Development
Intellia: Balancing in vivo risk with validated targets
Sticking with genetic targets validated by Alnylam and Ionis gave Intellia confidence to take CRISPR in vivo
BioCentury | Feb 20, 2025
Emerging Company Profile
Switch: Precision siRNA knockdown
San Francisco-based biotech is pursuing CNS diseases with three-stranded siRNAs that can target specific cell types within a tissue
BioCentury | Feb 14, 2025
Deals
Embrace the competition from China, says Maraganore
U.S. biotechs need to rise to the challenge and learn from their competitors
BioCentury | Jan 28, 2025
Distillery Therapeutics
Placenta-targeting LNP delivering VEGF mRNA for preeclampsia
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: New modality showdowns
Genetic therapies compete in the same indications, as degraders come of age
BioCentury | Dec 20, 2024
Emerging Company Profile
City: Taking RNAi beyond the liver
Maraganore’s latest RNA company pairs targeting tech with trigger molecules a fraction of the size of Alnylam’s
Items per page:
1 - 10 of 1021